NEW YORK (360Dx) – Finland-based Bone Index said Friday that it has received 510(k) clearance from the US Food and Drug Administration for a second-generation point-of-care diagnostic test for osteoporosis.  

The test, Bindex, uses ultrasound to measure the cortical bone thickness of the tibia and applies an algorithm to calculate the bone density index, an estimate of bone mineral density, at the hip.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.